The efficacy of combination immunotherapy with ipilimumab plus nivolumab in metastatic myxofibrosarcoma

Foteini Kalofonou; Andrea Napolitano; Charlotte Benson; Aisha Miah; Shane Zaidi; Daniel Lindsay; Khin Thway; Robin L Jones

doi:10.1177/20363613241290788

The efficacy of combination immunotherapy with ipilimumab plus nivolumab in metastatic myxofibrosarcoma

Rare Tumors. 2024 Nov 6:16:20363613241290788. doi: 10.1177/20363613241290788. eCollection 2024.

Authors

Foteini Kalofonou¹, Andrea Napolitano¹, Charlotte Benson¹, Aisha Miah¹, Shane Zaidi¹, Daniel Lindsay¹, Khin Thway¹, Robin L Jones¹

Affiliation

¹ Sarcoma Unit, The Royal Marsden Hospital and Institute of Cancer Research, London, UK.

Abstract

We present the case of a patient with Myxofibrosarcoma (MFS), a mesenchymal type of soft tissue sarcoma (STS) and the response to combination immunotherapy with anti PD-1 and anti-CTLA-4 therapy, following disease progression after Standard chemotherapy (SACT) and Radiotherapy (RT). We have shown a timeline of treatment and responses, as well as the overall safety profile and the management of immunotherapy related adverse events. This study demonstrates the potential of checkpoint inhibitors as therapeutic agents in the treatment of MFS.

Keywords: combination immunotherapy; immunotherapy outcome; ipilimumab; myxofibrosarcoma; nivolumab; rare tumors.

Publication types

Case Reports